Carmustine – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 70 min read

Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

On this page11 sections

Article Summary

Carmustine (BCNU) is a parenterally administered alkylating agent used alone and in combination with other antineoplastic agents in the treatment of several forms of cancer including leukemias, lymphomas, and breast, testicular, ovarian, gastric, and pancreatic cancer. Carmustine therapy is associated with minor transient serum enzyme elevations and has been linked to cases of acute liver injury including cholestatic hepatitis and acute venous-occlusive disease. Carmustine is...

Key Takeaways

This article explains Mechanism of Action in simple medical language.
This article explains Indications in simple medical language.
This article explains Use in Cancer in simple medical language.
This article explains Contraindication in simple medical language.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.

Educational health guideWritten for patient understanding and clinical awareness.

Reviewed content workflowUse writer and reviewer profiles for stronger trust.

Emergency safety firstUrgent warning signs are highlighted below.

Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Evidence Trust Passport

How this article is supported

72/100

Written byDr. Harun Ar Rashid, MD - Arthritis, Bones, Joints Pain, Trauma, and Internal Medicine Specialist

Medical review1 reviewer

Last reviewedNot scheduled

Next reviewNot scheduled

References1 source entry

Review statusReview schedule needed

Medical library classification Drug monograph Drugs A–Z

This passport makes the article’s review, evidence, and update signals visible. It does not guarantee that every section is complete or replace personal medical advice.

Definition

Carmustine (BCNU) is a parenterally administered alkylating agent used alone and in combination with other antineoplastic agents in the treatment of several forms of cancer including leukemias, lymphomas, and breast, testicular, ovarian, gastric, and pancreatic cancer. Carmustine therapy is associated with minor transient serum enzyme elevations and has been linked to cases of acute liver injury including cholestatic hepatitis and acute venous-occlusive disease.

Carmustine is an antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect. Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)

Carmustine is a member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group. It has a role as an alkylating agent and an antineoplastic agent. It is a member of N-nitrosoureas and an organochlorine compound.

Mechanism of Action

Carmustine causes cross-links in DNA and RNA, leading to the inhibition of DNA synthesis, RNA production, and RNA translation (protein synthesis). Carmustine also binds to and modifies (carbamoylates) glutathione reductase. This leads to cell death.

Temozolomide (TMZ) and carmustine (BCNU), cancer drugs usually used in the treatment of gliomas, are DNA-methylating agents producing O6-methylguanine. It has been shown that 06-methylguanine triggers DNA mismatch repair and in turn induces apoptosis and senescence, respectively, over a 4 and 6 days period. Temozolomide and carmustine have an earlier effect on the nuclear organization and chromatin structure. In particular, temozolomide and carmustine induce the clustering of pericentromeric heterochromatin regions and increase the number of heterochromatic proteins MeCP2 and HP1alpha bound to chromatin. These drugs also decrease global levels of histone H3 acetylation and increase levels of histone H3 trimethylated on lysine 9 (H3-triMeK9). These events precede the senescence status. … Temozolomide and carmustine efficacy in glioma treatment may implicate a first event characterized by changes in heterochromatin organization and its silencing which is then followed by apoptosis and senescence.

Indications

For the treatment of brain tumors, multiple myeloma, Hodgkin’s disease, and Non-Hodgkin’s lymphomas.
Carmustine is effective in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): Brain tumors (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma, and ependymoma), brain metastases, Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease as conditioning treatment prior to autologous hematopoietic progenitor cell transplantation (HPCT) in malignant hematological diseases.
Astrocytomas
Brain Stem Gliomas
Ependymomas
Glioblastoma Multiforme (GBM)
Medulloblastomas
Mycosis Fungoides (MF)
Newly Diagnosed High Grade Glioma (HGG)
Recurrent Glioblastoma Multiforme (GBM)
Refractory Hodgkin Lymphoma
Refractory Multiple Myeloma
Tumors Metastatic to Brain
Refractory Non-Hodgkin’s lymphoma

Use in Cancer

Carmustine is approved to be used alone or with other drugs to treat:

Brain tumors (certain types).
Hodgkin lymphoma. It is used with other drugs in patients whose disease has not gotten better with other treatment or has recurred (come back).
Multiple myeloma. It is used with prednisone.
Non-Hodgkin lymphoma. It is used with other drugs in patients whose disease has not gotten better with other treatment or has recurred (come back).

Carmustine is also being studied in the treatment of other types of cancer.

Contraindication

a bad infection
acute leukemia
anemia
decreased blood platelets
low levels of white blood cells
low levels of a type of white blood cell called neutrophils
bleeding
a condition where there is formation of fibrous tissue in the lung called pulmonary fibrosis
x-ray results showing lung tissue changes
liver problems
decreased kidney function
abnormal liver function tests
pregnancy
a patient who is producing milk and breastfeeding

Dosage

Strengths: 100 mg; 7.7 mg; 50 mg; 300 mg

Brain/Intracranial Tumor

IV:

As a single agent in previously untreated patients: 150 to 200 mg/m2 IV every 6 weeks administered as a single dose or divided into daily injections (75 to 100 mg/m2 IV on two successive days)
In combination with other myelosuppressive drugs or in patients in whom bone marrow reserve is depleted, doses should be adjusted accordingly.

Adjust doses after the initial dose according to the hematologic response of the patient to the preceding dose. The following schedule is suggested by the manufacturer as a guide:

Nadir after prior dose: Leukocytes greater than 4000/mm3 and platelets greater than 100,000/m3: Give 100% of the prior dose.
Nadir after prior dose: Leukocytes 3000 to 3999/mm3 and platelets 75,000 to 99,999/m3: Give 100% of the prior dose.
Nadir after prior dose: Leukocytes 2000 to 2999/mm3 and platelets 25,000 to 74,999/m3: Give 70% of the prior dose.
Nadir after prior dose: Leukocytes less than 2000/mm3 and platelets less than 25,000/m3: Give 50% of the prior dose

IV: As palliative therapy as a single agent or in combination therapy with other approved chemotherapeutic agents in the following:

Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors
Multiple myeloma in combination with prednisone
Relapsed or refractory Hodgkin’s lymphoma in combination with other approved drugs
Relapsed or refractory Non-Hodgkin’s lymphomas in combination with other approved drugs

Non-Hodgkin’s Lymphoma

IV:

As a single agent in previously untreated patients: 150 to 200 mg/m2 IV every 6 weeks administered as a single dose or divided into daily injections (75 to 100 mg/m2 IV on two successive days)
In combination with other myelosuppressive drugs or in patients in whom bone marrow reserve is depleted, doses should be adjusted accordingly.

Adjust doses after the initial dose according to the hematologic response of the patient to the preceding dose. The following schedule is suggested by the manufacturer as a guide:

Nadir after prior dose: Leukocytes greater than 4000/mm3 and platelets greater than 100,000/m3: Give 100% of the prior dose.
Nadir after prior dose: Leukocytes 3000 to 3999/mm3 and platelets 75,000 to 99,999/m3: Give 100% of the prior dose.
Nadir after prior dose: Leukocytes 2000 to 2999/mm3 and platelets 25,000 to 74,999/m3: Give 70% of the prior dose.
Nadir after prior dose: Leukocytes less than 2000/mm3 and platelets less than 25,000/m3: Give 50% of the prior dose.

IV: As palliative therapy as a single agent or in combination therapy with other approved chemotherapeutic agents in the following:

Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors
Multiple myeloma in combination with prednisone
Relapsed or refractory Hodgkin’s lymphoma in combination with other approved drugs
Relapsed or refractory Non-Hodgkin’s lymphomas in combination with other approved drugs

Hodgkin’s Disease

IV:

As a single agent in previously untreated patients: 150 to 200 mg/m2 IV every 6 weeks administered as a single dose or divided into daily injections (75 to 100 mg/m2 IV on two successive days)
In combination with other myelosuppressive drugs or in patients in whom bone marrow reserve is depleted, doses should be adjusted accordingly.

Adjust doses after the initial dose according to the hematologic response of the patient to the preceding dose. The following schedule is suggested by the manufacturer as a guide:

Nadir after prior dose: Leukocytes greater than 4000/mm3 and platelets greater than 100,000/m3: Give 100% of the prior dose.
Nadir after prior dose: Leukocytes 3000 to 3999/mm3 and platelets 75,000 to 99,999/m3: Give 100% of the prior dose.
Nadir after prior dose: Leukocytes 2000 to 2999/mm3 and platelets 25,000 to 74,999/m3: Give 70% of the prior dose.
Nadir after prior dose: Leukocytes less than 2000/mm3 and platelets less than 25,000/m3: Give 50% of the prior dose.

IV: As palliative therapy as a single agent or in combination therapy with other approved chemotherapeutic agents in the following:

Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors
Multiple myeloma in combination with prednisone
Relapsed or refractory Hodgkin’s lymphoma in combination with other approved drugs
Relapsed or refractory Non-Hodgkin’s lymphomas in combination with other approved drugs

Multiple Myeloma

IV:

As a single agent in previously untreated patients: 150 to 200 mg/m2 IV every 6 weeks administered as a single dose or divided into daily injections (75 to 100 mg/m2 IV on two successive days)
In combination with other myelosuppressive drugs or in patients in whom bone marrow reserve is depleted, doses should be adjusted accordingly.

Adjust doses after the initial dose according to the hematologic response of the patient to the preceding dose. The following schedule is suggested by the manufacturer as a guide:

Nadir after the prior dose: Leukocytes greater than 4000/mm3 and platelets greater than 100,000/m3: Give 100% of the prior dose.
Nadir after prior dose: Leukocytes 3000 to 3999/mm3 and platelets 75,000 to 99,999/m3: Give 100% of the prior dose.
Nadir after prior dose: Leukocytes 2000 to 2999/mm3 and platelets 25,000 to 74,999/m3: Give 70% of the prior dose.
Nadir after the prior dose: Leukocytes less than 2000/mm3 and platelets less than 25,000/m3: Give 50% of the prior dose.

IV: As palliative therapy as a single agent or in combination therapy with other approved chemotherapeutic agents in the following:

Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors
Multiple myeloma in combination with prednisone
Relapsed or refractory Hodgkin’s lymphoma in combination with other approved drugs
Relapsed or refractory Non-Hodgkin’s lymphomas in combination with other approved drugs

Glioblastoma Multiforme

WAFER:

Eight 7.7 mg wafers (61.6 mg total dose) were implanted intracranially

WAFER:

Newly-diagnosed high-grade glioma as an adjunct to surgery and radiation
Recurrent glioblastoma as an adjunct to surgery

Malignant Glioma

WAFER:

Eight 7.7 mg wafers (61.6 mg total dose) were implanted intracranially

Side Effects

The Most Common

nausea
vomiting
headache
loss of balance or coordination
pale skin
fainting
dizziness
fast or irregular heartbeat
chest pain
darkened skin
swelling, pain, redness, or burning at the injection site
Signs of an allergic reaction such as hives, rash, skin changes, difficulty breathing or talking, or swelling of the mouth, face, lips, tongue, or throat.
Nausea (interferes with the ability to eat and is unrelieved with prescribed medication).
upset stomach
extreme tiredness or weakness
lack of energy
loss of appetite
pain in the upper right part of the stomach
yellowing of the skin or eyes
decreased urination
swelling of the hands, feet, ankles, or lower legs
Carmustine injection may cause other side effects.

More Common

easy bruising, unusual bleeding;
a seizure;
unexplained weight loss;
little or no urination; or
pain, burning, swelling, or skin changes where the injection was given;
slow healing of your incision after carmustine implant placement;
lung problems–a dry cough or hack, shortness of breath (especially with exercise), rapid but shallow breathing, tiredness, body aches, clubbing (widening and rounding) of your fingertips or toes;
increased pressure inside your skull–sudden vision problems, severe headache, vomiting, dizziness; or
signs of meningitis–fever, neck stiffness, increased sensitivity to light, nausea, vomiting, confusion, and drowsiness.

Rare

difficulty breathing,
swelling of your face, lips, tongue, or throat,
skin redness,
eye redness,
severe warmth or tingling under your skin,
easy bruising,
unusual bleeding,
seizure,
unexplained weight loss,
little or no urination,
pain, burning, swelling, or skin changes where the injection was given,
slow healing of your incision after implant placement,
dry cough or hack,
shortness of breath,
rapid bur shallow breathing,
tiredness,
body aches,
clubbing (widening and rounding) of your fingertips or toes,
sudden vision problems,
severe headache,
vomiting,
dizziness,
neck stiffness,
increased sensitivity to light,
confusion, and
drowsiness

Interaction

DRUG	INTERACTION
Abacavir	Carmustine may decrease the excretion rate of Abacavir which could result in a higher serum level.
Abametapir	The serum concentration of Carmustine can be increased when it is combined with Abametapir.
Abatacept	The metabolism of Carmustine can be increased when combined with Abatacept.
Abciximab	The risk or severity of bleeding can be increased when Abciximab is combined with Carmustine.
Abiraterone	The serum concentration of Carmustine can be increased when it is combined with Abiraterone.
Aceclofenac	Aceclofenac may decrease the excretion rate of Carmustine which could result in a higher serum level.
Acemetacin	Acemetacin may decrease the excretion rate of Carmustine which could result in a higher serum level.
Acenocoumarol	The metabolism of Acenocoumarol can be decreased when combined with Carmustine.
Acetaminophen	The metabolism of Acetaminophen can be decreased when combined with Carmustine.
Acetazolamide	Acetazolamide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Acetyldigitoxin	Acetyldigitoxin may decrease the cardiotoxic activities of Carmustine.
Acetylsalicylic acid	The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Carmustine.
Aclidinium	Carmustine may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine	Carmustine may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Acyclovir	The metabolism of Acyclovir can be decreased when combined with Carmustine.
Adalimumab	The metabolism of Carmustine can be increased when combined with Adalimumab.
Adefovir dipivoxil	Adefovir dipivoxil may decrease the excretion rate of Carmustine which could result in a higher serum level.
Adenovirus type 7 vaccine live	The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Carmustine.
Agomelatine	The metabolism of Agomelatine can be decreased when combined with Carmustine.
Albendazole	The metabolism of Carmustine can be increased when combined with Albendazole.
Albutrepenonacog alfa	Carmustine may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Alclofenac	Alclofenac may decrease the excretion rate of Carmustine which could result in a higher serum level.
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Carmustine.
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Carmustine.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carmustine.
Allogeneic processed thymus tissue	The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Carmustine.
Allopurinol	The risk or severity of adverse effects can be increased when Allopurinol is combined with Carmustine.
Almasilate	Carmustine may decrease the excretion rate of Almasilate which could result in a higher serum level.
Almotriptan	Carmustine may decrease the excretion rate of Almotriptan which could result in a higher serum level.
Alogliptin	Carmustine may decrease the excretion rate of Alogliptin which could result in a higher serum level.
Alosetron	The metabolism of Carmustine can be decreased when combined with Alosetron.
Alprazolam	Carmustine may decrease the excretion rate of Alprazolam which could result in a higher serum level.
Alteplase	The risk or severity of bleeding can be increased when Alteplase is combined with Carmustine.
Altretamine	The risk or severity of adverse effects can be increased when Carmustine is combined with Altretamine.
Amantadine	Carmustine may decrease the excretion rate of Amantadine which could result in a higher serum level.
Amikacin	Carmustine may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiloride	Amiloride may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Aminophenazone	The metabolism of Aminophenazone can be decreased when combined with Carmustine.
Aminophylline	The metabolism of Aminophylline can be decreased when combined with Carmustine.
Amiodarone	The metabolism of Carmustine can be decreased when combined with Amiodarone.
Amitriptyline	The metabolism of Amitriptyline can be decreased when combined with Carmustine.
Ammonium chloride	Carmustine may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.
Amoxicillin	Carmustine may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
Amphetamine	Amphetamine may decrease the excretion rate of Carmustine which could result in a higher serum level.
Amphotericin B	Amphotericin B may decrease the excretion rate of Carmustine which could result in a higher serum level.
Ampicillin	Carmustine may decrease the excretion rate of Ampicillin which could result in a higher serum level.
Amrinone	Carmustine may decrease the excretion rate of Amrinone which could result in a higher serum level.
Amsacrine	The risk or severity of adverse effects can be increased when Carmustine is combined with Amsacrine.
Anagrelide	The metabolism of Carmustine can be decreased when combined with Anagrelide.
Anakinra	The metabolism of Carmustine can be increased when combined with Anakinra.
Anastrozole	The risk or severity of cardiotoxicity can be increased when Carmustine is combined with Anastrozole.
Ancestim	Carmustine may decrease the excretion rate of Ancestim which could result in a higher serum level.
Ancrod	The risk or severity of bleeding can be increased when Ancrod is combined with Carmustine.
Anifrolumab	The risk or severity of adverse effects can be increased when Carmustine is combined with Anifrolumab.
Anistreplase	The risk or severity of bleeding can be increased when Anistreplase is combined with Carmustine.
Anthrax immune	The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Carmustine.
Anthrax vaccine	The risk or severity of infection can be increased when Anthrax vaccine is combined with Carmustine.
Antihemophilic	Carmustine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.
Antilymphocyte	The risk or severity of adverse effects can be increased when Carmustine is combined with Antilymphocyte immunoglobulin (horse).
Antipyrine	The metabolism of Antipyrine can be decreased when combined with Carmustine.
Antithrombin Alfa	The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Carmustine.
Antithrombin III human	Carmustine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
Antithymocyte	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Carmustine.
Antrafenine	Antrafenine may decrease the excretion rate of Carmustine which could result in a higher serum level.
Apalutamide	Carmustine may decrease the excretion rate of Apalutamide which could result in a higher serum level.
Apixaban	The risk or severity of bleeding can be increased when Apixaban is combined with Carmustine.
Apremilast	The metabolism of Carmustine can be increased when combined with Apremilast.
Ardeparin	The risk or severity of bleeding can be increased when Ardeparin is combined with Carmustine.
Arformoterol	Carmustine may decrease the excretion rate of Arformoterol which could result in a higher serum level.
Argatroban	The risk or severity of bleeding can be increased when Argatroban is combined with Carmustine.
Armodafinil	The metabolism of Carmustine can be increased when combined with Armodafinil.
Arsenic trioxide	The risk or severity of adverse effects can be increased when Carmustine is combined with Arsenic trioxide.
Articaine	The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Articaine.
Asenapine	The metabolism of Asenapine can be decreased when combined with Carmustine.
COVID-19 Vaccine	The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Carmustine.
Atazanavir	The metabolism of Carmustine can be decreased when combined with Atazanavir.
Atomoxetine	Carmustine may decrease the excretion rate of Atomoxetine which could result in a higher serum level.
Auranofin	Carmustine may decrease the excretion rate of Auranofin which could result in a higher serum level.
Aurothioglucose	Carmustine may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.
Axitinib	The metabolism of Axitinib can be decreased when combined with Carmustine.
Azacitidine	The risk or severity of adverse effects can be increased when Carmustine is combined with Azacitidine.
Azathioprine	The risk or severity of adverse effects can be increased when Carmustine is combined with Azathioprine.
Azelaic acid	Carmustine may decrease the excretion rate of Azelaic acid which could result in a higher serum level.
Azelastine	The metabolism of Azelastine can be decreased when combined with Carmustine.
Aztreonam	Carmustine may decrease the excretion rate of Aztreonam which could result in a higher serum level.
Bacillus calmette-	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Carmustine.
Bacillus calmette-	The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Carmustine.
Bacillus calmette	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Carmustine.
Bacitracin	Bacitracin may decrease the excretion rate of Carmustine which could result in a higher serum level.
Baclofen	Baclofen may decrease the excretion rate of Carmustine which could result in a higher serum level.
Balsalazide	Balsalazide may decrease the excretion rate of Carmustine which could result in a higher serum level.
Baricitinib	The risk or severity of adverse effects can be increased when Carmustine is combined with Baricitinib.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Carmustine.
BCG vaccine	The risk or severity of infection can be increased when BCG vaccine is combined with Carmustine.
Beclomethasone dipropionate	The risk or severity of adverse effects can be increased when Carmustine is combined with Beclomethasone dipropionate.
Belatacept	The risk or severity of adverse effects can be increased when Carmustine is combined with Belatacept.
Belimumab	The risk or severity of adverse effects can be increased when Carmustine is combined with Belimumab.
Belinostat	The risk or severity of adverse effects can be increased when Carmustine is combined with Belinostat.
Belumosudil	The risk or severity of adverse effects can be increased when Carmustine is combined with Belumosudil.
Bemiparin	The risk or severity of bleeding can be increased when Bemiparin is combined with Carmustine.

Bendamustine	The risk or severity of adverse effects can be increased when Carmustine is combined with Bendamustine.
Bendroflumethiazide	Bendroflumethiazide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Benorilate	Benorilate may decrease the excretion rate of Carmustine which could result in a higher serum level.
Benoxaprofen	Benoxaprofen may decrease the excretion rate of Carmustine which could result in a higher serum level.
Benserazide	Carmustine may decrease the excretion rate of Benserazide which could result in a higher serum level.
Benzatropine	Benzatropine may decrease the excretion rate of Carmustine which could result in a higher serum level.
Benznidazole	Carmustine may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Benzocaine	The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Benzocaine.
Benzthiazide	Benzthiazide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Benzydamine	Benzydamine may decrease the excretion rate of Carmustine which could result in a higher serum level.
Benzyl alcohol	The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Benzyl alcohol.
Bepotastine	Carmustine may decrease the excretion rate of Bepotastine which could result in a higher serum level.
Betamethasone	The risk or severity of adverse effects can be increased when Carmustine is combined with Betamethasone.
Betaxolol	The metabolism of Carmustine can be decreased when combined with Betaxolol.
Betrixaban	The risk or severity of bleeding can be increased when Betrixaban is combined with Carmustine.
Bevacizumab	The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Carmustine.
Bexarotene	The risk or severity of adverse effects can be increased when Carmustine is combined with Bexarotene.
Bicisate	Carmustine may decrease the excretion rate of Bicisate which could result in a higher serum level.
Bimekizumab	The metabolism of Carmustine can be increased when combined with Bimekizumab.
Binimetinib	The metabolism of Binimetinib can be decreased when combined with Carmustine.
Bismuth subgallate	Carmustine may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
Bisoprolol	Carmustine may decrease the excretion rate of Bisoprolol which could result in a higher serum level.
Bisoxatin	Carmustine may decrease the excretion rate of Bisoxatin which could result in a higher serum level.
Bivalirudin	The risk or severity of bleeding can be increased when Bivalirudin is combined with Carmustine.
Bleomycin	The risk or severity of adverse effects can be increased when Carmustine is combined with Bleomycin.
Blinatumomab	The risk or severity of adverse effects can be increased when Carmustine is combined with Blinatumomab.
Bordetella pertussis	The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Carmustine.
Bortezomib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Carmustine.
Bosutinib	The risk or severity of adverse effects can be increased when Carmustine is combined with Bosutinib.
Brentuximab vedotin	The risk or severity of adverse effects can be increased when Carmustine is combined with Brentuximab vedotin.
Brivaracetam	Carmustine may decrease the excretion rate of Brivaracetam which could result in a higher serum level.
Brodalumab	The risk or severity of adverse effects can be increased when Carmustine is combined with Brodalumab.
Bromazepam	The metabolism of Bromazepam can be decreased when combined with Carmustine.
Bromotheophylline	Bromotheophylline may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Budesonide	The risk or severity of adverse effects can be increased when Carmustine is combined with Budesonide.
Bumadizone	Bumadizone may decrease the excretion rate of Carmustine which could result in a higher serum level.
Bumetanide	Bumetanide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Bupivacaine	The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Bupivacaine.
Bupropion	Carmustine may decrease the excretion rate of Bupropion which could result in a higher serum level.
Buspirone	Carmustine may decrease the excretion rate of Buspirone which could result in a higher serum level.
Busulfan	The risk or severity of adverse effects can be increased when Carmustine is combined with Busulfan.
Butabarbital	Butabarbital may decrease the excretion rate of Carmustine which could result in a higher serum level.
Butacaine	The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Butacaine.
Butamben	The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Butamben.
Cabazitaxel	The risk or severity of adverse effects can be increased when Carmustine is combined with Cabazitaxel.
Caffeine	The metabolism of Carmustine can be decreased when combined with Caffeine.
Canagliflozin	Canagliflozin may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Canakinumab	The metabolism of Carmustine can be increased when combined with Canakinumab.
Cangrelor	The risk or severity of bleeding can be increased when Cangrelor is combined with Carmustine.
Cannabidiol	The metabolism of Carmustine can be decreased when combined with Cannabidiol.
Canrenoic acid	Canrenoic acid may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Capecitabine	The risk or severity of adverse effects can be increased when Carmustine is combined with Capecitabine.
Caplacizumab	The risk or severity of bleeding can be increased when Caplacizumab is combined with Carmustine.
Capmatinib	The metabolism of Carmustine can be decreased when combined with Capmatinib.
Capreomycin	Carmustine may decrease the excretion rate of Capreomycin which could result in a higher serum level.
Capsaicin	The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Capsaicin.
Carbamazepine	The risk or severity of adverse effects can be increased when Carmustine is combined with Carbamazepine.
Carbidopa	Carbidopa may decrease the excretion rate of Carmustine which could result in a higher serum level.
Carboplatin	The risk or severity of adverse effects can be increased when Carmustine is combined with Carboplatin.
Carfilzomib	The risk or severity of adverse effects can be increased when Carmustine is combined with Carfilzomib.
Carprofen	Carprofen may decrease the excretion rate of Carmustine which could result in a higher serum level.
Carvedilol	The metabolism of Carvedilol can be decreased when combined with Carmustine.
Cefaclor	Cefaclor may decrease the excretion rate of Carmustine which could result in a higher serum level.
Cefadroxil	Cefadroxil may decrease the excretion rate of Carmustine which could result in a higher serum level.
Cefalotin	Cefalotin may decrease the excretion rate of Carmustine which could result in a higher serum level.
Cefamandole	Cefamandole may decrease the excretion rate of Carmustine which could result in a higher serum level.
Cefapirin	Cefapirin may decrease the excretion rate of Carmustine which could result in a higher serum level.
Cefazolin	Cefazolin may decrease the excretion rate of Carmustine which could result in a higher serum level.
Cefdinir	Carmustine may decrease the excretion rate of Cefdinir which could result in a higher serum level.
Cefditoren	Cefditoren may decrease the excretion rate of Carmustine which could result in a higher serum level.
Cefepime	Cefepime may decrease the excretion rate of Carmustine which could result in a higher serum level.
Cefmenoxime	Cefmenoxime may decrease the excretion rate of Carmustine which could result in a higher serum level.
Cefmetazole	Cefmetazole may decrease the excretion rate of Carmustine which could result in a higher serum level.
Cefonicid	Cefonicid may decrease the excretion rate of Carmustine which could result in a higher serum level.
Cefoperazone	Cefoperazone may decrease the excretion rate of Carmustine which could result in a higher serum level.
Ceforanide	Ceforanide may decrease the excretion rate of Carmustine which could result in a higher serum level.
Cefotaxime	Cefotaxime may decrease the excretion rate of Carmustine which could result in a higher serum level.
Cefotetan	Cefotetan may decrease the excretion rate of Carmustine which could result in a higher serum level.
Cefotiam	Cefotiam may decrease the excretion rate of Carmustine which could result in a higher serum level.
Cefoxitin	Cefoxitin may decrease the excretion rate of Carmustine which could result in a higher serum level.
Cefpiramide	Cefpiramide may decrease the excretion rate of Carmustine which could result in a higher serum level.
Cefpirome	Cefpirome may decrease the excretion rate of Carmustine which could result in a higher serum level.
Cefpodoxime	Cefpodoxime may decrease the excretion rate of Carmustine which could result in a higher serum level.
Cefprozil	Cefprozil may decrease the excretion rate of Carmustine which could result in a higher serum level.
Cefradine	Cefradine may decrease the excretion rate of Carmustine which could result in a higher serum level.
Ceftaroline fosamil	Ceftaroline fosamil may decrease the excretion rate of Carmustine which could result in a higher serum level.
Ceftazidime	Ceftazidime may decrease the excretion rate of Carmustine which could result in a higher serum level.
Ceftibuten	Ceftibuten may decrease the excretion rate of Carmustine which could result in a higher serum level.
Ceftizoxime	Ceftizoxime may decrease the excretion rate of Carmustine which could result in a higher serum level.
Ceftobiprole	Ceftobiprole may decrease the excretion rate of Carmustine which could result in a higher serum level.
Ceftolozane	Carmustine may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
Ceftriaxone	Ceftriaxone may decrease the excretion rate of Carmustine which could result in a higher serum level.
Cefuroxime	Cefuroxime may decrease the excretion rate of Carmustine which could result in a higher serum level.
Celecoxib	Celecoxib may decrease the excretion rate of Carmustine which could result in a higher serum level.
Cephalexin	Cephalexin may decrease the excretion rate of Carmustine which could result in a higher serum level.
Cephaloglycin	Cephaloglycin may decrease the excretion rate of Carmustine which could result in a higher serum level.
Certolizumab pegol	The metabolism of Carmustine can be increased when combined with Certolizumab pegol.
Cetirizine	Carmustine may decrease the excretion rate of Cetirizine which could result in a higher serum level.
Cevimeline	Cevimeline may decrease the excretion rate of Carmustine which could result in a higher serum level.
Chloral hydrate	Carmustine may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.

Chloramphenicol	The risk or severity of adverse effects can be increased when Carmustine is combined with Chloramphenicol.
Chloroprocaine	The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Chloroprocaine.
Chloroquine	Carmustine may decrease the excretion rate of Chloroquine which could result in a higher serum level.
Chlorothiazide	Chlorothiazide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Chloroxylenol	Carmustine may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.
Chlorpromazine	The metabolism of Chlorpromazine can be decreased when combined with Carmustine.
Chlorpropamide	Carmustine may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.
Chlorthalidone	Chlorthalidone may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Chlorzoxazone	The metabolism of Chlorzoxazone can be decreased when combined with Carmustine.
Choline C 11	Carmustine may decrease the excretion rate of Choline C 11 which could result in a higher serum level.
Choline magnesium trisalicylate	Choline magnesium trisalicylate may decrease the excretion rate of Carmustine which could result in a higher serum level.
Choline salicylate	Carmustine may decrease the excretion rate of Choline salicylate which could result in a higher serum level.
Chondroitin sulfate	Carmustine may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
Chromic chloride	Carmustine may decrease the excretion rate of Chromic chloride which could result in a higher serum level.
Chromic nitrate	Carmustine may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.
Chromium	Carmustine may decrease the excretion rate of Chromium which could result in a higher serum level.
Chromium gluconate	Carmustine may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.
Chromium nicotinate	Carmustine may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
Chromous sulfate	Carmustine may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.
Ciclesonide	The risk or severity of adverse effects can be increased when Carmustine is combined with Ciclesonide.
Cidofovir	Cidofovir may decrease the excretion rate of Carmustine which could result in a higher serum level.
Cilostazol	The metabolism of Cilostazol can be decreased when combined with Carmustine.
Cimetidine	Cimetidine may increase the myelosuppressive activities of Carmustine.
Cinacalcet	The metabolism of Cinacalcet can be decreased when combined with Carmustine.
Cinchocaine	The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Cinchocaine.
Cinnarizine	The metabolism of Cinnarizine can be decreased when combined with Carmustine.
Cinoxacin	The metabolism of Carmustine can be decreased when combined with Cinoxacin.
Ciprofloxacin	The metabolism of Carmustine can be decreased when combined with Ciprofloxacin.
Cisplatin	The risk or severity of adverse effects can be increased when Carmustine is combined with Cisplatin.
Citalopram	The metabolism of Carmustine can be decreased when combined with Citalopram.
Cladribine	The risk or severity of adverse effects can be increased when Cladribine is combined with Carmustine.
Clevidipine	Carmustine may decrease the excretion rate of Clevidipine which could result in a higher serum level.
Clobazam	Carmustine may decrease the excretion rate of Clobazam which could result in a higher serum level.
Clobetasol propionate	The risk or severity of adverse effects can be increased when Carmustine is combined with Clobetasol propionate.
Clofarabine	The risk or severity of adverse effects can be increased when Carmustine is combined with Clofarabine.
Clomipramine	The metabolism of Clomipramine can be decreased when combined with Carmustine.
Clonazepam	Carmustine may decrease the excretion rate of Clonazepam which could result in a higher serum level.
Clonidine	The metabolism of Clonidine can be decreased when combined with Carmustine.
Clopidogrel	The metabolism of Clopidogrel can be decreased when combined with Carmustine.
Clorazepic acid	Carmustine may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.
Clostridium	The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Carmustine.
Clove oil	Carmustine may decrease the excretion rate of Clove oil which could result in a higher serum level.
Clozapine	The risk or severity of neutropenia can be increased when Carmustine is combined with Clozapine.
Cocaine	The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Cocaine.
Colchicine	Carmustine may decrease the excretion rate of Colchicine which could result in a higher serum level.
Colistimethate	Colistimethate may decrease the excretion rate of Carmustine which could result in a higher serum level.
Colistin	Carmustine may decrease the excretion rate of Colistin which could result in a higher serum level.
Conivaptan	Conivaptan may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Conjugated estrogens	The metabolism of Conjugated estrogens can be decreased when combined with Carmustine.
Corifollitropin alfa	Carmustine may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.
Corticotropin	The risk or severity of adverse effects can be increased when Carmustine is combined with Corticotropin.
Cortisone acetate	The risk or severity of adverse effects can be increased when Carmustine is combined with Cortisone acetate.
Corynebacterium	The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Carmustine.
Curcumin	The metabolism of Carmustine can be decreased when combined with Curcumin.
Cyanocobalamin	The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Carmustine.
Cyclobenzaprine	The metabolism of Cyclobenzaprine can be decreased when combined with Carmustine.
Cyclopenthiazide	Cyclopenthiazide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Cyclophosphamide	The risk or severity of adverse effects can be increased when Carmustine is combined with Cyclophosphamide.
Cyclosporine	Carmustine may increase the immunosuppressive activities of Cyclosporine.
Cyclothiazide	Cyclothiazide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Cyproterone acetate	The metabolism of Carmustine can be increased when combined with Cyproterone acetate.
Cytarabine	The risk or severity of adverse effects can be increased when Carmustine is combined with Cytarabine.
Dabigatran	The risk or severity of bleeding can be increased when Dabigatran is combined with Carmustine.
Dabigatran etexilate	Carmustine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.
Dacarbazine	The risk or severity of adverse effects can be increased when Carmustine is combined with Dacarbazine.
Dactinomycin	The risk or severity of adverse effects can be increased when Carmustine is combined with Dactinomycin.
Dalfampridine	Carmustine may decrease the excretion rate of Dalfampridine which could result in a higher serum level.
Dalteparin	The risk or severity of bleeding can be increased when Dalteparin is combined with Carmustine.
Danaparoid	The risk or severity of bleeding can be increased when Danaparoid is combined with Carmustine.
Dapagliflozin	Dapagliflozin may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Daptomycin	Daptomycin may decrease the excretion rate of Carmustine which could result in a higher serum level.
Darbepoetin alfa	The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Carmustine.
Dasatinib	The risk or severity of adverse effects can be increased when Carmustine is combined with Dasatinib.
Daunorubicin	The risk or severity of adverse effects can be increased when Carmustine is combined with Daunorubicin.
Decitabine	The risk or severity of adverse effects can be increased when Carmustine is combined with Decitabine.
Deferasirox	The serum concentration of Carmustine can be increased when it is combined with Deferasirox.
Deferiprone	Carmustine may decrease the excretion rate of Deferiprone which could result in a higher serum level.
Defibrotide	The risk or severity of bleeding can be increased when Defibrotide is combined with Carmustine.
Deflazacort	The risk or severity of adverse effects can be increased when Carmustine is combined with Deflazacort.
Delafloxacin	Carmustine may decrease the excretion rate of Delafloxacin which could result in a higher serum level.
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Carmustine.
Desipramine	Carmustine may decrease the excretion rate of Desipramine which could result in a higher serum level.
Desirudin	The risk or severity of bleeding can be increased when Desirudin is combined with Carmustine.
Deslanoside	Deslanoside may decrease the cardiotoxic activities of Carmustine.
Desmopressin	Desmopressin may decrease the excretion rate of Carmustine which could result in a higher serum level.
Desoximetasone	The risk or severity of adverse effects can be increased when Carmustine is combined with Desoximetasone.
Desvenlafaxine	Carmustine may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.
Deucravacitinib	The risk or severity of adverse effects can be increased when Carmustine is combined with Deucravacitinib.
Deutetrabenazine	Carmustine may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.
Dexamethasone	The risk or severity of adverse effects can be increased when Carmustine is combined with Dexamethasone.
Dexfenfluramine	The metabolism of Dexfenfluramine can be decreased when combined with Carmustine.
Dexibuprofen	Dexibuprofen may decrease the excretion rate of Carmustine which could result in a higher serum level.
Dexketoprofen	Dexketoprofen may decrease the excretion rate of Carmustine which could result in a higher serum level.
Dexmedetomidine	The metabolism of Carmustine can be decreased when combined with Dexmedetomidine.
Dexpanthenol	Carmustine may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
Dexrazoxane	The risk or severity of adverse effects can be increased when Carmustine is combined with Dexrazoxane.
Dextran	Carmustine may decrease the excretion rate of Dextran which could result in a higher serum level.
Diacerein	The metabolism of Carmustine can be decreased when combined with Diacerein.
Diatrizoate	Carmustine may decrease the excretion rate of Diatrizoate which could result in a higher serum level.

Diazepam	Carmustine may decrease the excretion rate of Diazepam which could result in a higher serum level.
Dichlorobenzyl alcohol	Carmustine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.
Diclofenac	The metabolism of Diclofenac can be decreased when combined with Carmustine.
Diclofenamide	Diclofenamide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Dicoumarol	The risk or severity of bleeding can be increased when Dicoumarol is combined with Carmustine.
Dicyclomine	Carmustine may decrease the excretion rate of Dicyclomine which could result in a higher serum level.
Didanosine	Carmustine may decrease the excretion rate of Didanosine which could result in a higher serum level.
Dienogest	Carmustine may decrease the excretion rate of Dienogest which could result in a higher serum level.
Diflunisal	Diflunisal may decrease the excretion rate of Carmustine which could result in a higher serum level.
Difluocortolone	The risk or severity of adverse effects can be increased when Carmustine is combined with Difluocortolone.
Digitoxin	Digitoxin may decrease the cardiotoxic activities of Carmustine.
Digoxin	Carmustine may decrease the excretion rate of Digoxin which could result in a higher serum level.
Dihydralazine	The metabolism of Carmustine can be decreased when combined with Dihydralazine.
Dihydrostreptomycin	Dihydrostreptomycin may decrease the excretion rate of Carmustine which could result in a higher serum level.
Dimercaprol	Carmustine may decrease the excretion rate of Dimercaprol which could result in a higher serum level.
Dimethyl fumarate	The risk or severity of adverse effects can be increased when Carmustine is combined with Dimethyl fumarate.
Dimethyl sulfoxide	Carmustine may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.
Dinutuximab	The risk or severity of adverse effects can be increased when Carmustine is combined with Dinutuximab.
Diphenhydramine	The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Diphenhydramine.
Dipyridamole	The risk or severity of bleeding can be increased when Dipyridamole is combined with Carmustine.
Diroximel fumarate	The risk or severity of adverse effects can be increased when Carmustine is combined with Diroximel fumarate.
Disopyramide	The metabolism of Disopyramide can be decreased when combined with Carmustine.
DL-Methylephedrine	Carmustine may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.
Dobutamine	Carmustine may decrease the excretion rate of Dobutamine which could result in a higher serum level.
Docetaxel	The risk or severity of adverse effects can be increased when Carmustine is combined with Docetaxel.
Domperidone	The metabolism of Domperidone can be decreased when combined with Carmustine.
Dopamine	Carmustine may decrease the excretion rate of Dopamine which could result in a higher serum level.
Doripenem	Carmustine may decrease the excretion rate of Doripenem which could result in a higher serum level.
Dosulepin	The metabolism of Carmustine can be decreased when combined with Dosulepin.
Doxacurium	Carmustine may decrease the excretion rate of Doxacurium which could result in a higher serum level.
Doxepin	The metabolism of Doxepin can be decreased when combined with Carmustine.
Doxorubicin	The risk or severity of adverse effects can be increased when Carmustine is combined with Doxorubicin.
Doxycycline	Doxycycline may decrease the excretion rate of Carmustine which could result in a higher serum level.
Dronabinol	The metabolism of Carmustine can be decreased when combined with Dronabinol.
Drospirenone	Drospirenone may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Drotrecogin alfa	The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Carmustine.
Droxidopa	Carmustine may decrease the excretion rate of Droxidopa which could result in a higher serum level.
Duloxetine	Carmustine may decrease the excretion rate of Duloxetine which could result in a higher serum level.
Dyclonine	The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Dyclonine.
Dyphylline	Carmustine may decrease the excretion rate of Dyphylline which could result in a higher serum level.
Ebola Zaire vaccine (live, attenuated)	The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Carmustine.
Eculizumab	The risk or severity of adverse effects can be increased when Carmustine is combined with Eculizumab.
Edetic acid	The risk or severity of bleeding can be increased when Edetic acid is combined with Carmustine.
Edoxaban	Carmustine may decrease the excretion rate of Edoxaban which could result in a higher serum level.
Edrophonium	Carmustine may decrease the excretion rate of Edrophonium which could result in a higher serum level.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Carmustine.
Efavirenz	The metabolism of Carmustine can be decreased when combined with Efavirenz.
Eltrombopag	The metabolism of Eltrombopag can be decreased when combined with Carmustine.
Emapalumab	The metabolism of Carmustine can be increased when combined with Emapalumab.
Enalaprilat	Carmustine may decrease the excretion rate of Enalaprilat which could result in a higher serum level.
Enasidenib	The metabolism of Carmustine can be decreased when combined with Enasidenib.
Enoxacin	The metabolism of Carmustine can be decreased when combined with Enoxacin.
Enoxaparin	The risk or severity of bleeding can be increased when Enoxaparin is combined with Carmustine.
Entecavir	The metabolism of Entecavir can be decreased when combined with Carmustine.
Enzalutamide	Carmustine may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
Epirubicin	The risk or severity of adverse effects can be increased when Carmustine is combined with Epirubicin.
Eplerenone	Eplerenone may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Epoprostenol	The risk or severity of bleeding can be increased when Epoprostenol is combined with Carmustine.
Eptifibatide	The risk or severity of bleeding can be increased when Eptifibatide is combined with Carmustine.
Eribulin	The risk or severity of adverse effects can be increased when Carmustine is combined with Eribulin.
Erlotinib	The metabolism of Erlotinib can be decreased when combined with Carmustine.
Ertapenem	Carmustine may decrease the excretion rate of Ertapenem which could result in a higher serum level.
Ertugliflozin	Ertugliflozin may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Erythropoietin	The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Carmustine.
Estazolam	Carmustine may decrease the excretion rate of Estazolam which could result in a higher serum level.
Estradiol	The metabolism of Estradiol can be decreased when combined with Carmustine.
Estradiol acetate	The metabolism of Carmustine can be decreased when combined with Estradiol acetate.
Estradiol benzoate	The metabolism of Estradiol benzoate can be decreased when combined with Carmustine.
Estradiol cypionate	The metabolism of Estradiol cypionate can be decreased when combined with Carmustine.
Estradiol dienanthate	The metabolism of Estradiol dienanthate can be decreased when combined with Carmustine.
Estradiol valerate	The metabolism of Estradiol valerate can be decreased when combined with Carmustine.
Estramustine	The risk or severity of adverse effects can be increased when Carmustine is combined with Estramustine.
Estrone sulfate	The metabolism of Carmustine can be decreased when combined with Estrone sulfate.
Eszopiclone	Carmustine may decrease the excretion rate of Eszopiclone which could result in a higher serum level.
Etacrynic acid	Etacrynic acid may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Etafedrine	Carmustine may decrease the excretion rate of Etafedrine which could result in a higher serum level.
Etanercept	The metabolism of Carmustine can be increased when combined with Etanercept.
Ethambutol	Carmustine may decrease the excretion rate of Ethambutol which could result in a higher serum level.
Ethanol	The metabolism of Ethanol can be decreased when combined with Carmustine.
Ethinylestradiol	The metabolism of Ethinylestradiol can be decreased when combined with Carmustine.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Ethyl chloride.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Etidocaine.
Etodolac	Etodolac may decrease the excretion rate of Carmustine which could result in a higher serum level.
Etomidate	Carmustine may decrease the excretion rate of Etomidate which could result in a higher serum level.
Etonogestrel	Carmustine may decrease the excretion rate of Etonogestrel which could result in a higher serum level.
Etoposide	The risk or severity of adverse effects can be increased when Carmustine is combined with Etoposide.
Etoricoxib	The metabolism of Etoricoxib can be decreased when combined with Carmustine.
Eucalyptus oil	Carmustine may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Everolimus	The risk or severity of adverse effects can be increased when Carmustine is combined with Everolimus.
Ezogabine	Carmustine may decrease the excretion rate of Ezogabine which could result in a higher serum level.
Famotidine	The metabolism of Carmustine can be decreased when combined with Famotidine.
Fenbufen	Fenbufen may decrease the excretion rate of Carmustine which could result in a higher serum level.
Fenfluramine	The metabolism of Fenfluramine can be decreased when combined with Carmustine.
Fenofibrate	Carmustine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Fenofibric acid	Carmustine may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.
Fenoldopam	Carmustine may decrease the excretion rate of Fenoldopam which could result in a higher serum level.
Fenoprofen	Fenoprofen may decrease the excretion rate of Carmustine which could result in a higher serum level.
Fentanyl	Carmustine may decrease the excretion rate of Fentanyl which could result in a higher serum level.
Fesoterodine	Carmustine may decrease the excretion rate of Fesoterodine which could result in a higher serum level.
Fexinidazole	The metabolism of Carmustine can be decreased when combined with Fexinidazole.

Filgotinib	The risk or severity of adverse effects can be increased when Carmustine is combined with Filgotinib.
Finerenone	Finerenone may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Fingolimod	Carmustine may increase the immunosuppressive activities of Fingolimod.
Flavoxate	Carmustine may decrease the excretion rate of Flavoxate which could result in a higher serum level.
Flecainide	The metabolism of Flecainide can be decreased when combined with Carmustine.
Floctafenine	Floctafenine may decrease the excretion rate of Carmustine which could result in a higher serum level.
Florbetaben (18F)	Carmustine may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
Florbetapir (18F)	Carmustine may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
Floxuridine	The risk or severity of adverse effects can be increased when Carmustine is combined with Floxuridine.
Fluconazole	Fluconazole may decrease the excretion rate of Carmustine which could result in a higher serum level.
Flucytosine	The risk or severity of adverse effects can be increased when Carmustine is combined with Flucytosine.
Fludarabine	The risk or severity of adverse effects can be increased when Carmustine is combined with Fludarabine.
Fludeoxyglucose (18F)	Carmustine may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
Fludrocortisone	The risk or severity of adverse effects can be increased when Carmustine is combined with Fludrocortisone.
Fluindione	The risk or severity of bleeding can be increased when Fluindione is combined with Carmustine.
Flumazenil	Carmustine may decrease the excretion rate of Flumazenil which could result in a higher serum level.
Flunarizine	The metabolism of Flunarizine can be decreased when combined with Carmustine.
Flunisolide	The risk or severity of adverse effects can be increased when Flunisolide is combined with Carmustine.
Fluocinolone acetonide	The risk or severity of adverse effects can be increased when Carmustine is combined with Fluocinolone acetonide.
Fluocinonide	The risk or severity of adverse effects can be increased when Carmustine is combined with Fluocinonide.
Fluocortolone	The risk or severity of adverse effects can be increased when Carmustine is combined with Fluocortolone.
Fluorometholone	The risk or severity of adverse effects can be increased when Carmustine is combined with Fluorometholone.
Fluorouracil	The risk or severity of adverse effects can be increased when Carmustine is combined with Fluorouracil.
Fluoxetine	The metabolism of Carmustine can be decreased when combined with Fluoxetine.
Flupentixol	The risk or severity of myelosuppression can be increased when Flupentixol is combined with Carmustine.
Fluprednisolone	The risk or severity of adverse effects can be increased when Carmustine is combined with Fluprednisolone.
Flurazepam	Carmustine may decrease the excretion rate of Flurazepam which could result in a higher serum level.
Flurbiprofen	Flurbiprofen may decrease the excretion rate of Carmustine which could result in a higher serum level.
Flutamide	The metabolism of Flutamide can be decreased when combined with Carmustine.
Fluticasone	The risk or severity of adverse effects can be increased when Carmustine is combined with Fluticasone.
Fluticasone furoate	The risk or severity of adverse effects can be increased when Carmustine is combined with Fluticasone furoate.
Fluticasone propionate	The risk or severity of adverse effects can be increased when Carmustine is combined with Fluticasone propionate.
Fluvoxamine	The metabolism of Carmustine can be decreased when combined with Fluvoxamine.
Folic acid	Folic acid may decrease the excretion rate of Carmustine which could result in a higher serum level.
Fomepizole	Carmustine may decrease the excretion rate of Fomepizole which could result in a higher serum level.
Fondaparinux	Carmustine may decrease the excretion rate of Fondaparinux which could result in a higher serum level.
Formestane	Carmustine may decrease the excretion rate of Formestane which could result in a higher serum level.
Foscarnet	Foscarnet may decrease the excretion rate of Carmustine which could result in a higher serum level.
Fosfomycin	Carmustine may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
Fosinopril	Carmustine may decrease the excretion rate of Fosinopril which could result in a higher serum level.
Fosphenytoin	The serum concentration of Fosphenytoin can be decreased when it is combined with Carmustine.
Framycetin	Framycetin may decrease the excretion rate of Carmustine which could result in a higher serum level.
Frovatriptan	The metabolism of Frovatriptan can be decreased when combined with Carmustine.
Furosemide	Furosemide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Gabapentin enacarbil	Carmustine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.
Gadobenic acid	Carmustine may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.
Gadodiamide	Gadodiamide may decrease the excretion rate of Carmustine which could result in a higher serum level.
Gadofosveset trisodium	Carmustine may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Gadopentetic acid	Carmustine may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.
Gadoteric acid	Carmustine may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
Gadoteridol	Carmustine may decrease the excretion rate of Gadoteridol which could result in a higher serum level.
Gallium nitrate	The risk or severity of adverse effects can be increased when Carmustine is combined with Gallium nitrate.
Ganciclovir	Carmustine may decrease the excretion rate of Ganciclovir which could result in a higher serum level.
Gatifloxacin	The metabolism of Carmustine can be decreased when combined with Gatifloxacin.
Gemcitabine	The risk or severity of adverse effects can be increased when Carmustine is combined with Gemcitabine.
Gemfibrozil	The metabolism of Carmustine can be decreased when combined with Gemfibrozil.
Gemifloxacin	The metabolism of Carmustine can be decreased when combined with Gemifloxacin.
Gemtuzumab ozogamicin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carmustine.
Gentamicin	Carmustine may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Gimeracil	Carmustine may decrease the excretion rate of Gimeracil which could result in a higher serum level.
Givosiran	The serum concentration of Carmustine can be increased when it is combined with Givosiran.
Glatiramer	The risk or severity of adverse effects can be increased when Carmustine is combined with Glatiramer.
Glipizide	Carmustine may decrease the excretion rate of Glipizide which could result in a higher serum level.
Glycerol phenylbutyrate	Carmustine may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.
Golimumab	The metabolism of Carmustine can be increased when combined with Golimumab.
Golodirsen	Carmustine may decrease the excretion rate of Golodirsen which could result in a higher serum level.
Goserelin	Goserelin may decrease the excretion rate of Carmustine which could result in a higher serum level.
Grepafloxacin	The metabolism of Carmustine can be decreased when combined with Grepafloxacin.
Guanabenz	The metabolism of Guanabenz can be decreased when combined with Carmustine.
Guanethidine	Carmustine may decrease the excretion rate of Guanethidine which could result in a higher serum level.
Guanfacine	Carmustine may decrease the excretion rate of Guanfacine which could result in a higher serum level.
Guselkumab	The risk or severity of adverse effects can be increased when Carmustine is combined with Guselkumab.

Lumiracoxib	Lumiracoxib may decrease the excretion rate of Carmustine which could result in a higher serum level.
Macitentan	Carmustine may decrease the excretion rate of Macitentan which could result in a higher serum level.
Magnesium	The serum concentration of Magnesium can be decreased when it is combined with Carmustine.
Magnesium carbonate	Carmustine may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.
Magnesium chloride	Carmustine may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
Magnesium hydroxide	Carmustine may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Magnesium trisilicate	Carmustine may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
Mangafodipir	Carmustine may decrease the excretion rate of Mangafodipir which could result in a higher serum level.
Mannitol	Mannitol may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Maprotiline	The metabolism of Maprotiline can be decreased when combined with Carmustine.
Measles virus	The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Carmustine.
Mecamylamine	Carmustine may decrease the excretion rate of Mecamylamine which could result in a higher serum level.
Mechlorethamine	The risk or severity of adverse effects can be increased when Carmustine is combined with Mechlorethamine.
Meclofenamic acid	Meclofenamic acid may decrease the excretion rate of Carmustine which could result in a higher serum level.
Medroxyprogesterone	Carmustine may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.
Mefenamic acid	The metabolism of Mefenamic acid can be decreased when combined with Carmustine.
Megestrol acetate	Carmustine may decrease the excretion rate of Megestrol acetate which could result in a higher serum level.
Melatonin	The metabolism of Melatonin can be decreased when combined with Carmustine.
Meloxicam	The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Meloxicam.
Melphalan	The risk or severity of pulmonary toxicity can be increased when Melphalan is combined with Carmustine.
Memantine	Carmustine may decrease the excretion rate of Memantine which could result in a higher serum level.
Meningococcal	The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Carmustine.
Meperidine	Carmustine may decrease the excretion rate of Meperidine which could result in a higher serum level.
Mephenytoin	The metabolism of Mephenytoin can be decreased when combined with Carmustine.
Mepivacaine	The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Mepivacaine.
Mepolizumab	The risk or severity of adverse effects can be increased when Carmustine is combined with Mepolizumab.
Meprednisone	The risk or severity of adverse effects can be increased when Carmustine is combined with Meprednisone.
Mercaptopurine	The risk or severity of adverse effects can be increased when Carmustine is combined with Mercaptopurine.
Meropenem	Carmustine may decrease the excretion rate of Meropenem which could result in a higher serum level.
Mesalazine	Mesalazine may decrease the excretion rate of Carmustine which could result in a higher serum level.
Metamfetamine	Carmustine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Metamizole	Metamizole may decrease the excretion rate of Carmustine which could result in a higher serum level.
Metaxalone	Carmustine may decrease the excretion rate of Metaxalone which could result in a higher serum level.
Metformin	Carmustine may decrease the excretion rate of Metformin which could result in a higher serum level.
Methadone	Carmustine may decrease the excretion rate of Methadone which could result in a higher serum level.
Methazolamide	Methazolamide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Methimazole	The risk or severity of adverse effects can be increased when Carmustine is combined with Methimazole.
Methotrexate	The risk or severity of adverse effects can be increased when Carmustine is combined with Methotrexate.
Methoxsalen	The metabolism of Carmustine can be decreased when combined with Methoxsalen.
Methoxy polyethylene	The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Carmustine.
Methyldopa	Carmustine may decrease the excretion rate of Methyldopa which could result in a higher serum level.
Methylene blue	The metabolism of Carmustine can be increased when combined with Methylene blue.
Methylnaltrexone	Carmustine may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
Methylprednisolone	The risk or severity of adverse effects can be increased when Carmustine is combined with Methylprednisolone.
Methyltestosterone	Carmustine may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.
Meticrane	Meticrane may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Metoclopramide	The metabolism of Metoclopramide can be decreased when combined with Carmustine.
Metolazone	Metolazone may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Metoprolol	Carmustine may decrease the excretion rate of Metoprolol which could result in a higher serum level.
Metyrapone	Carmustine may decrease the excretion rate of Metyrapone which could result in a higher serum level.
Mexiletine	The metabolism of Carmustine can be decreased when combined with Mexiletine.
Mianserin	The metabolism of Mianserin can be decreased when combined with Carmustine.
Midazolam	Carmustine may decrease the excretion rate of Midazolam which could result in a higher serum level.
Migalastat	Carmustine may decrease the excretion rate of Migalastat which could result in a higher serum level.
Milnacipran	Carmustine may decrease the excretion rate of Milnacipran which could result in a higher serum level.
Milrinone	Milrinone may decrease the excretion rate of Carmustine which could result in a higher serum level.
Mirabegron	Carmustine may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Mirtazapine	The metabolism of Mirtazapine can be decreased when combined with Carmustine.
Mitomycin	The risk or severity of adverse effects can be increased when Carmustine is combined with Mitomycin.
Mitoxantrone	The risk or severity of adverse effects can be increased when Carmustine is combined with Mitoxantrone.
COVID-19 Vaccine	The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Carmustine.
Modified vaccinia ankara	The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Carmustine.
Mometasone furoate	The risk or severity of adverse effects can be increased when Carmustine is combined with Mometasone furoate.
Monomethyl fumarate	The risk or severity of adverse effects can be increased when Carmustine is combined with Monomethyl fumarate.
Mosunetuzumab	The risk or severity of adverse effects can be increased when Carmustine is combined with Mosunetuzumab.
Moxifloxacin	The metabolism of Carmustine can be decreased when combined with Moxifloxacin.
Moxisylyte	Carmustine may decrease the excretion rate of Moxisylyte which could result in a higher serum level.

Norfloxacin	The metabolism of Carmustine can be decreased when combined with Norfloxacin.
Nuvaxovid	The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Carmustine.
Obeticholic acid	The metabolism of Carmustine can be decreased when combined with Obeticholic acid.
Obinutuzumab	The risk or severity of adverse effects can be increased when Carmustine is combined with Obinutuzumab.
Ocrelizumab	Ocrelizumab may increase the immunosuppressive activities of Carmustine.
Octinoxate	Carmustine may decrease the excretion rate of Octinoxate which could result in a higher serum level.
Ofatumumab	The risk or severity of adverse effects can be increased when Carmustine is combined with Ofatumumab.
Olanzapine	The metabolism of Olanzapine can be decreased when combined with Carmustine.
Olaparib	The risk or severity of adverse effects can be increased when Carmustine is combined with Olaparib.
Olsalazine	Olsalazine may decrease the excretion rate of Carmustine which could result in a higher serum level.
Omeprazole	The metabolism of Carmustine can be increased when combined with Omeprazole.
Ondansetron	The metabolism of Ondansetron can be decreased when combined with Carmustine.
Opium	Carmustine may decrease the excretion rate of Opium which could result in a higher serum level.
Orphenadrine	The metabolism of Carmustine can be decreased when combined with Orphenadrine.
Oseltamivir	Oseltamivir may decrease the excretion rate of Carmustine which could result in a higher serum level.
Osilodrostat	The metabolism of Carmustine can be decreased when combined with Osilodrostat.
Osimertinib	The serum concentration of Carmustine can be decreased when it is combined with Osimertinib.
Ouabain	Ouabain may decrease the cardiotoxic activities of Carmustine.
Oxacillin	Carmustine may decrease the excretion rate of Oxacillin which could result in a higher serum level.
Oxaliplatin	The risk or severity of adverse effects can be increased when Carmustine is combined with Oxaliplatin.
Oxaprozin	Oxaprozin may decrease the excretion rate of Carmustine which could result in a higher serum level.
Oxazepam	Carmustine may decrease the excretion rate of Oxazepam which could result in a higher serum level.
Oxetacaine	The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Oxetacaine.
Oxtriphylline	The metabolism of Oxtriphylline can be decreased when combined with Carmustine.
Oxybenzone	Carmustine may decrease the excretion rate of Oxybenzone which could result in a higher serum level.
Oxybuprocaine	The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Oxybuprocaine.
Oxyphenbutazone	Oxyphenbutazone may decrease the excretion rate of Carmustine which could result in a higher serum level.
Oxyquinoline	Carmustine may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
Ozanimod	The risk or severity of adverse effects can be increased when Carmustine is combined with Ozanimod.
Paclitaxel	The risk or severity of adverse effects can be increased when Carmustine is combined with Paclitaxel.
Pacritinib	The metabolism of Carmustine can be decreased when combined with Pacritinib.
Palbociclib	The risk or severity of adverse effects can be increased when Carmustine is combined with Palbociclib.
Palifermin	The therapeutic efficacy of Palifermin can be decreased when used in combination with Carmustine.
Paliperidone	Carmustine may decrease the excretion rate of Paliperidone which could result in a higher serum level.
Palonosetron	Carmustine may decrease the excretion rate of Palonosetron which could result in a higher serum level.
Pamidronic acid	Pamidronic acid may decrease the excretion rate of Carmustine which could result in a higher serum level.
Panobinostat	The risk or severity of adverse effects can be increased when Carmustine is combined with Panobinostat.
Pantoprazole	Pantoprazole may decrease the excretion rate of Carmustine which could result in a higher serum level.
Parecoxib	Parecoxib may decrease the excretion rate of Carmustine which could result in a higher serum level.
Parnaparin	The risk or severity of bleeding can be increased when Parnaparin is combined with Carmustine.
Paromomycin	Paromomycin may decrease the excretion rate of Carmustine which could result in a higher serum level.
Paroxetine	The metabolism of Paroxetine can be decreased when combined with Carmustine.
Patent Blue	Carmustine may decrease the excretion rate of Patent Blue which could result in a higher serum level.
Pazopanib	The risk or severity of adverse effects can be increased when Carmustine is combined with Pazopanib.
Pefloxacin	The metabolism of Carmustine can be decreased when combined with Pefloxacin.
Pegaptanib	Carmustine may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
Pegaspargase	The risk or severity of adverse effects can be increased when Pegaspargase is combined with Carmustine.
Pegcetacoplan	The risk or severity of adverse effects can be increased when Carmustine is combined with Pegcetacoplan.
Peginesatide	The risk or severity of Thrombosis can be increased when Peginesatide is combined with Carmustine.
Peginterferon alfa-2a	The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Carmustine.
Peginterferon alfa-2b	The serum concentration of Carmustine can be increased when it is combined with Peginterferon alfa-2b.
Peginterferon beta-1a	The risk or severity of adverse effects can be increased when Carmustine is combined with Peginterferon beta-1a.
Pemetrexed	The risk or severity of adverse effects can be increased when Carmustine is combined with Pemetrexed.
Penbutolol	Carmustine may decrease the excretion rate of Penbutolol which could result in a higher serum level.
Penciclovir	The metabolism of Penciclovir can be decreased when combined with Carmustine.
Penicillamine	The risk or severity of adverse effects can be increased when Carmustine is combined with Penicillamine.
Pentaerythritol tetranitrate	Carmustine may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.
Pentamidine	Pentamidine may decrease the excretion rate of Carmustine which could result in a higher serum level.
Pentastarch	Carmustine may decrease the excretion rate of Pentastarch which could result in a higher serum level.
Pentetic acid	Carmustine may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
Pentobarbital	Carmustine may decrease the excretion rate of Pentobarbital which could result in a higher serum level.
Pentosan polysulfate	The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Carmustine.
Pentostatin	The risk or severity of adverse effects can be increased when Carmustine is combined with Pentostatin.
Pentoxifylline	The metabolism of Pentoxifylline can be decreased when combined with Carmustine.
Perampanel	The metabolism of Perampanel can be decreased when combined with Carmustine.
Perindopril	Carmustine may decrease the excretion rate of Perindopril which could result in a higher serum level.
Permethrin	Carmustine may decrease the excretion rate of Permethrin which could result in a higher serum level.
Perphenazine	The metabolism of Perphenazine can be decreased when combined with Carmustine.
Pertussis vaccine	The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Carmustine.
Pertuzumab	The risk or severity of cardiotoxicity can be increased when Carmustine is combined with Pertuzumab.
Phenazopyridine	Phenazopyridine may decrease the excretion rate of Carmustine which could result in a higher serum level.
Phenelzine	Carmustine may decrease the excretion rate of Phenelzine which could result in a higher serum level.
Phenindione	The risk or severity of bleeding can be increased when Phenindione is combined with Carmustine.
Phenol	The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Phenol.
Phenprocoumon	The risk or severity of bleeding can be increased when Phenprocoumon is combined with Carmustine.
Phentolamine	Carmustine may decrease the excretion rate of Phentolamine which could result in a higher serum level.
Phenylalanine	The risk or severity of adverse effects can be increased when Phenylalanine is combined with Carmustine.
Phenylbutazone	Phenylbutazone may decrease the excretion rate of Carmustine which could result in a higher serum level.
Phenylephrine	The metabolism of Carmustine can be increased when combined with Phenylephrine.
Phenytoin	The serum concentration of Phenytoin can be decreased when it is combined with Carmustine.
Pholcodine	Carmustine may decrease the excretion rate of Pholcodine which could result in a higher serum level.
Phosphoric acid	Carmustine may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
Phylloquinone	Carmustine may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
Picosulfuric acid	Carmustine may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Carmustine.
Pimozide	The metabolism of Pimozide can be decreased when combined with Carmustine.
Pindolol	Carmustine may decrease the excretion rate of Pindolol which could result in a higher serum level.
Piperacillin	Carmustine may decrease the excretion rate of Piperacillin which could result in a higher serum level.
Piracetam	Carmustine may decrease the excretion rate of Piracetam which could result in a higher serum level.
Piretanide	Piretanide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Pirfenidone	The risk or severity of adverse effects can be increased when Carmustine is combined with Pirfenidone.
Piroxicam	Piroxicam may decrease the excretion rate of Carmustine which could result in a higher serum level.
Pitolisant	The metabolism of Carmustine can be increased when combined with Pitolisant.
Plazomicin	Carmustine may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Plerixafor	Carmustine may decrease the excretion rate of Plerixafor which could result in a higher serum level.
Polythiazide	Polythiazide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Pomalidomide	The risk or severity of adverse effects can be increased when Carmustine is combined with Pomalidomide.
Ponatinib	The risk or severity of adverse effects can be increased when Carmustine is combined with Ponatinib.
Ponesimod	The risk or severity of adverse effects can be increased when Carmustine is combined with Ponesimod.

Pramocaine	The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Pramocaine.
Prasugrel	The risk or severity of bleeding can be increased when Prasugrel is combined with Carmustine.
Praziquantel	The metabolism of Praziquantel can be decreased when combined with Carmustine.
Prednisolone	The risk or severity of adverse effects can be increased when Carmustine is combined with Prednisolone.
Prednisone	The risk or severity of adverse effects can be increased when Carmustine is combined with Prednisone.
Pregabalin	Pregabalin may decrease the excretion rate of Carmustine which could result in a higher serum level.
Prilocaine	The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Prilocaine.
Primaquine	The metabolism of Carmustine can be increased when combined with Primaquine.
Primidone	The metabolism of Carmustine can be increased when combined with Primidone.
Probenecid	Carmustine may decrease the excretion rate of Probenecid which could result in a higher serum level.
Procainamide	Carmustine may decrease the excretion rate of Procainamide which could result in a higher serum level.
Procaine	The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Procaine.
Procaine	Carmustine may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Procarbazine	The risk or severity of adverse effects can be increased when Carmustine is combined with Procarbazine.
Promazine	The metabolism of Carmustine can be decreased when combined with Promazine.
Promethazine	Carmustine may decrease the excretion rate of Promethazine which could result in a higher serum level.
Propafenone	The metabolism of Carmustine can be decreased when combined with Propafenone.
Propantheline	Carmustine may decrease the excretion rate of Propantheline which could result in a higher serum level.
Proparacaine	The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Proparacaine.
Propiverine	Carmustine may decrease the excretion rate of Propiverine which could result in a higher serum level.
Propoxycaine	The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Propoxycaine.
Propranolol	The metabolism of Propranolol can be decreased when combined with Carmustine.
Propylthiouracil	The risk or severity of adverse effects can be increased when Carmustine is combined with Propylthiouracil.
Protein C	The risk or severity of bleeding can be increased when Protein C is combined with Carmustine.
Protein S human	The risk or severity of bleeding can be increased when Protein S human is combined with Carmustine.
Prucalopride	Carmustine may decrease the excretion rate of Prucalopride which could result in a higher serum level.
Pyrantel	Carmustine may decrease the excretion rate of Pyrantel which could result in a higher serum level.
Pyrazinamide	Carmustine may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.
Pyridoxine	Pyridoxine may decrease the excretion rate of Carmustine which could result in a higher serum level.
Pyrithione	Carmustine may decrease the excretion rate of Pyrithione which could result in a higher serum level.
Quetiapine	Carmustine may decrease the excretion rate of Quetiapine which could result in a higher serum level.
Quinethazone	Quinethazone may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.
Quinidine	The metabolism of Carmustine can be decreased when combined with Quinidine.
Quinine	The metabolism of Quinine can be decreased when combined with Carmustine.
Rabeprazole	Carmustine may decrease the excretion rate of Rabeprazole which could result in a higher serum level.
Rabies immune	The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Carmustine.
Rabies virus A	The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Carmustine.
Rabies virus B	The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Carmustine.
Raltitrexed	The risk or severity of adverse effects can be increased when Carmustine is combined with Raltitrexed.
Ramelteon	The metabolism of Ramelteon can be decreased when combined with Carmustine.
Ranitidine	The metabolism of Ranitidine can be decreased when combined with Carmustine.
Ranolazine	Ranolazine may decrease the excretion rate of Carmustine which could result in a higher serum level.
Rasagiline	The metabolism of Rasagiline can be decreased when combined with Carmustine.
Ravulizumab	The risk or severity of adverse effects can be increased when Carmustine is combined with Ravulizumab.
Reserpine	Reserpine may decrease the excretion rate of Carmustine which could result in a higher serum level.
Resorcinol	Carmustine may decrease the excretion rate of Resorcinol which could result in a higher serum level.
Reteplase	The risk or severity of bleeding can be increased when Reteplase is combined with Carmustine.
Reviparin	The risk or severity of bleeding can be increased when Reviparin is combined with Carmustine.
Ribavirin	Carmustine may decrease the excretion rate of Ribavirin which could result in a higher serum level.
Ribostamycin	Carmustine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.
Rifampicin	The metabolism of Carmustine can be increased when combined with Rifampicin.
Rifamycin	The metabolism of Carmustine can be decreased when combined with Rifamycin.
Rilonacept	The metabolism of Carmustine can be increased when combined with Rilonacept.
Riluzole	The metabolism of Riluzole can be decreased when combined with Carmustine.
Risankizumab	The risk or severity of adverse effects can be increased when Carmustine is combined with Risankizumab.
Ritonavir	The metabolism of Carmustine can be increased when combined with Ritonavir.
Rituximab	The risk or severity of adverse effects can be increased when Rituximab is combined with Carmustine.
Rivaroxaban	Carmustine may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
Rizatriptan	Carmustine may decrease the excretion rate of Rizatriptan which could result in a higher serum level.
Rofecoxib	The metabolism of Carmustine can be decreased when combined with Rofecoxib.
Roflumilast	Roflumilast may increase the immunosuppressive activities of Carmustine.
Ropeginterferon	The risk or severity of adverse effects can be increased when Carmustine is combined with Ropeginterferon alfa-2b.
Ropivacaine	The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Ropivacaine.
Rosiglitazone	Carmustine may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.
Rosoxacin	The metabolism of Carmustine can be decreased when combined with Rosoxacin.
Rotavirus vaccine	The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Carmustine.
Rubella virus vaccine	The risk or severity of infection can be increased when Rubella virus vaccine is combined with Carmustine.
Rucaparib	The metabolism of Carmustine can be increased when combined with Rucaparib.
Ruxolitinib	The risk or severity of adverse effects can be increased when Carmustine is combined with Ruxolitinib.
Sacubitril	Carmustine may decrease the excretion rate of Sacubitril which could result in a higher serum level.
Salbutamol	Carmustine may decrease the excretion rate of Salbutamol which could result in a higher serum level.
Salicylamide	Salicylamide may decrease the excretion rate of Carmustine which could result in a higher serum level.
Salicylic acid	Salicylic acid may decrease the excretion rate of Carmustine which could result in a higher serum level.
Salmon calcitonin	Salmon calcitonin may decrease the excretion rate of Carmustine which could result in a higher serum level.
Salsalate	Salsalate may decrease the excretion rate of Carmustine which could result in a higher serum level.
Sarilumab	The risk or severity of adverse effects can be increased when Carmustine is combined with Sarilumab.
Satralizumab	The serum concentration of Carmustine can be decreased when it is combined with Satralizumab.
Saxagliptin	Carmustine may decrease the excretion rate of Saxagliptin which could result in a higher serum level.
Secobarbital	Carmustine may decrease the excretion rate of Secobarbital which could result in a higher serum level.
Secukinumab	The metabolism of Carmustine can be increased when combined with Secukinumab.
Selegiline	The metabolism of Selegiline can be decreased when combined with Carmustine.
Selenious acid	Carmustine may decrease the excretion rate of Selenious acid which could result in a higher serum level.
Selenium	Carmustine may decrease the excretion rate of Selenium which could result in a higher serum level.
Selumetinib	The metabolism of Selumetinib can be decreased when combined with Carmustine.
Sibutramine	Carmustine may decrease the excretion rate of Sibutramine which could result in a higher serum level.
Siltuximab	The metabolism of Carmustine can be increased when combined with Siltuximab.
Simeprevir	The metabolism of Carmustine can be decreased when combined with Simeprevir.
Siponimod	The risk or severity of adverse effects can be increased when Carmustine is combined with Siponimod.

Pregnancy and Lactation

AU TGA pregnancy category: D
US FDA pregnancy category: Not assigned.

Pregnancy

Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details.

Lactation

No information is available on the use of carmustine during breastfeeding. Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy, especially alkylating agents such as carmustine.[1] The manufacturer recommends that breastfeeding be discontinued during carmustine therapy and for 1 month after the last dose.

How should this medicine be used?

Carmustine injection comes as a powder to be added to fluid and injected over at least 2 hours intravenously (into a vein) by a doctor or nurse in a medical office or hospital outpatient clinic. It is usually injected once every 6 weeks. It may also be injected in smaller doses once a day for 2 days in a row every 6 weeks.

Your doctor may need to delay your treatment or adjust your dose if you experience certain side effects. It is important for you to tell your doctor how you are feeling during your treatment with carmustine.

Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.

What special precautions should I follow?

Before receiving a carmustine injection,

tell your doctor and pharmacist if you are allergic to carmustine or any of the ingredients in the carmustine injection. Ask your pharmacist for a list of the ingredients.
tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, and nutritional supplements, you are taking or plan to take. Be sure to mention any of the following: cimetidine (Tagamet) and phenytoin (Dilantin). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Other medications may also interact with carmustine, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
tell your doctor if you have or have ever had kidney or liver disease.
tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. You should not become pregnant while you are receiving carmustine injections. If you become pregnant while receiving carmustine, call your doctor. Carmustine may harm the fetus.

References

https://pubchem.ncbi.nlm.nih.gov/compound/Carmustine
https://go.drugbank.com/drugs/DB00262
https://medlineplus.gov/druginfo/meds/a682060.html
https://www.drugs.com/pregnancy/carmustine.html
https://www.webmd.com/drugs/2/drug-19920/carmustine-intravenous/details/list-contraindications
ChemIDplus

LICENSE

https://www.nlm.nih.gov/copyright.html

Carmustine [USAN:USP:INN:BAN]

https://chem.nlm.nih.gov/chemidplus/sid/0000154938

ChemIDplus Chemical Information Classification

https://chem.nlm.nih.gov/chemidplus/
DrugBank

https://www.drugbank.ca/legal/terms_of_use

Carmustine

https://www.drugbank.ca/drugs/DB00262
DTP/NCI

https://www.cancer.gov/policies/copyright-reuse

carmustine

https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=758392

carmustine

https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=409962
EPA DSSTox

LICENSE

https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources

N,N’-Bis(2-chloroethyl)-N-nitrosourea

https://comptox.epa.gov/dashboard/DTXSID8022743

CompTox Chemicals Dashboard Chemical Lists

https://comptox.epa.gov/dashboard/chemical-lists/
European Chemicals Agency (ECHA)

https://echa.europa.eu/web/guest/legal-notice

Carmustine

https://echa.europa.eu/substance-information/-/substanceinfo/100.005.309

Carmustine

https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/21558
FDA Global Substance Registration System (GSRS)

https://www.fda.gov/about-fda/about-website/website-policies#linking

CARMUSTINE

https://gsrs.ncats.nih.gov/ginas/app/beta/substances/U68WG3173Y
Hazardous Substances Data Bank (HSDB)

Carmustine

https://pubchem.ncbi.nlm.nih.gov/source/hsdb/7761
Human Metabolome Database (HMDB)

http://www.hmdb.ca/citing

Carmustine

http://www.hmdb.ca/metabolites/HMDB0014407
ChEBI

Carmustine

http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3423

ChEBI Ontology

http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology
FDA Pharm Classes

https://www.fda.gov/about-fda/about-website/website-policies#linking

CARMUSTINE

https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm

FDA Pharmacological Classification

https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm
LiverTox

LICENSE

https://www.nlm.nih.gov/copyright.html

Carmustine

https://www.ncbi.nlm.nih.gov/books/n/livertox/Carmustine/
NCI Thesaurus (NCIt)

https://www.cancer.gov/policies/copyright-reuse

https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C349

NCI Thesaurus Tree

https://ncit.nci.nih.gov
ChEMBL

http://www.ebi.ac.uk/Information/termsofuse.html

https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL513/

ChEMBL Protein Target Tree

https://www.ebi.ac.uk/chembl/g/#browse/targets
Comparative Toxicogenomics Database (CTD)

http://ctdbase.org/about/legal.jsp

https://ctdbase.org/detail.go?type=chem&acc=D002330
Drug Gene Interaction database (DGIdb)

http://www.dgidb.org/downloads

https://www.dgidb.org/drugs/CARMUSTINE
Therapeutic Target Database (TTD)

DTI-015

http://idrblab.net/ttd/data/drug/details/D01OXI
ClinicalTrials.gov

https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use

https://clinicaltrials.gov/
DailyMed

LICENSE

https://www.nlm.nih.gov/copyright.html

CARMUSTINE

https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=CARMUSTINE
European Medicines Agency (EMA)

https://www.ema.europa.eu/en/about-us/legal-notice

Carmustine Obvius (EMEA/H/C/004326)

https://www.ema.europa.eu/en/medicines/human/EPAR/carmustine-obvius
Drugs and Lactation Database (LactMed)

LICENSE

https://www.nlm.nih.gov/copyright.html

Carmustine

https://www.ncbi.nlm.nih.gov/books/NBK500930/
EU Clinical Trials Register

https://www.clinicaltrialsregister.eu/
NITE-CMC

1,3-Bis(2-chloroethyl)-1-nitrosourea, (alias Carmustine) – FY2009

https://www.nite.go.jp/chem/english/ghs/09-mhlw-0228e.html
FDA Orange Book

https://www.fda.gov/about-fda/about-website/website-policies#linking

https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
WHO Anatomical Therapeutic Chemical (ATC) Classification

https://www.whocc.no/copyright_disclaimer/

https://www.whocc.no/atc/

ATC Code

https://www.whocc.no/atc_ddd_index/
National Drug Code (NDC) Directory

https://www.fda.gov/about-fda/about-website/website-policies#linking

CARMUSTINE

https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
International Agency for Research on Cancer (IARC)

https://publications.iarc.fr/Terms-Of-Use

Bischloroethyl nitrosourea (BCNU)

https://monographs.iarc.who.int/list-of-classifications

IARC Classification

https://www.iarc.fr/
NCI Cancer Drugs

LICENSE

https://www.cancer.gov/policies/copyright-reuse

BiCNU (Carmustine)

https://www.cancer.gov/about-cancer/treatment/drugs/carmustine
NIPH Clinical Trials Search of Japan

https://rctportal.niph.go.jp/en/
NIST Mass Spectrometry Data Center

LICENSE

https://www.nist.gov/srd/public-law

Carmustine

http://www.nist.gov/srd/nist1a.cfm
SpectraBase

1-(2-Chloroethyl)-1-([(2-chloroethyl)amino]carbonyl)-2-oxohydrazine

https://spectrabase.com/spectrum/73fQc6DWEGO

1,3-BIS-(2-CHLOROETHYL)-1-NITROSOUREA

https://spectrabase.com/spectrum/JouNlDITbxU

1,3-BIS-(2-CHLOROETHYL)-1-NITROSOUREA

https://spectrabase.com/spectrum/FUCaY5zpoyP

1,3-Bis-(2-chloroethyl)-1-nitrosourea

https://spectrabase.com/spectrum/8TQ7XYPzHNm

1,3-Bis-(2-chloroethyl)-1-nitrosourea

https://spectrabase.com/spectrum/3kMiqrOt1H1
NLM RxNorm Terminology

https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html

https://rxnav.nlm.nih.gov/id/rxnorm/2105
Springer Nature

https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=12051101-340277020
SpringerMaterials

Urea, N,N’-bis(2-chloroethyl)-N-nitroso-

https://materials.springer.com/substanceprofile/docs/smsid_aiybodkazgirkrhd
Thieme Chemistry

LICENSE

The Thieme Chemistry contribution within PubChem is provided under a CC-BY-NC-ND 4.0 license, unless otherwise stated.

https://creativecommons.org/licenses/by-nc-nd/4.0/

https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=12051101-340277411
Wikidata

LICENSE

CCZero

https://creativecommons.org/publicdomain/zero/1.0/

Carmustine

https://www.wikidata.org/wiki/Q415869
Wiley

https://pubchem.ncbi.nlm.nih.gov/substance/?source=wiley&sourceid=141573
Medical Subject Headings (MeSH)

https://www.nlm.nih.gov/copyright.html

Carmustine

https://www.ncbi.nlm.nih.gov/mesh/68002330

MeSH Tree

http://www.nlm.nih.gov/mesh/meshhome.html

Antineoplastic Agents, Alkylating

https://www.ncbi.nlm.nih.gov/mesh/68018906
PubChem

https://pubchem.ncbi.nlm.nih.gov
KEGG

LICENSE

Academic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial license

https://www.kegg.jp/kegg/legal.html

Therapeutic category of drugs in Japan

http://www.genome.jp/kegg-bin/get_htext?br08301.keg

Anatomical Therapeutic Chemical (ATC) classification

http://www.genome.jp/kegg-bin/get_htext?br08303.keg

Drug Groups

http://www.genome.jp/kegg-bin/get_htext?br08330.keg
UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)

GHS Classification Tree

http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
IUPHAR/BPS Guide to PHARMACOLOGY

https://www.guidetopharmacology.org/about.jsp#license

Guide to Pharmacology Target Classification

https://www.guidetopharmacology.org/targets.jsp
NORMAN Suspect List Exchange

LICENSE

Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0

https://creativecommons.org/licenses/by/4.0/

NORMAN Suspect List Exchange Classification

https://www.norman-network.com/nds/SLE/
EPA Substance Registry Services

LICENSE

https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources

EPA SRS List Classification

https://sor.epa.gov/sor_internet/registry/substreg/LandingPage.do
PATENTSCOPE (WIPO)

SID 403417922

https://pubchem.ncbi.nlm.nih.gov/substance/403417922
NCBI

https://www.ncbi.nlm.nih.gov/projects/linkout

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

Write when the problem started and how it changed.
Bring old prescriptions, investigation reports, and current medicines.
Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

What is the most likely cause of my symptoms?
Which danger signs mean I should go to hospital quickly?
Which tests are necessary now, and which can wait?
How should I take medicines safely and what side effects should I watch for?
When should I come for follow-up?

Tests to discuss

Vital signs: temperature, pulse, blood pressure, oxygen saturation
Basic physical examination by a clinician
CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

Avoid heavy lifting, sudden bending, and prolonged bed rest.
Use comfortable posture and gentle movement as tolerated.
Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

Do not start antibiotics without a proper medical decision.
Do not use steroid tablets or injections casually for quick relief.
Do not delay emergency care because of home remedies.

Get urgent help if

Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.

Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician

Tests to discuss with doctor

Temperature chart and hydration assessment
CBC with platelet count if fever persists or dengue/other infection is possible
Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated

Questions to ask

What is the most likely cause of my symptoms?
Which warning signs mean I should go to emergency care?
Which tests are really needed now?
Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Go to emergency care if you notice:

Severe or rapidly worsening symptoms
Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration

Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.

Step 1
Check danger signs first

If danger signs are present, seek emergency care and do not wait for online information.
Step 2
Record the symptom story

Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.
Step 3
Visit a qualified clinician

A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.
Step 4
Do only useful tests

Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.
Step 5
Follow up and return early if worse

If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips

Take a written symptom diary and all previous prescriptions/test reports.
Do not hide medicines already taken, even herbal or over-the-counter medicines.
Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

Internal learning pathway

Explore related RX articles

Related guides from RX Harun are grouped to help readers move from overview to symptoms, tests, treatment, and safe next steps.

Drugs (A - Z)

Vasodilator Drugs Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium…
Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine…
Methamphetamine – Uses, Dosage, Side Effects, Interactions Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.…
Vitamin D3 – Uses, Dosage, Side Effects, Interactions DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from…
Imidazole – Uses, Dosage, Side Effects, Interactions DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of…
Carbimazole Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is…

Read, save, and share this guide

Article Summary

Key Takeaways

RX Patient Tools

Mechanism of Action

Indications

Use in Cancer

Contraindication?

Dosage?

Brain/Intracranial Tumor?

Non-Hodgkin’s Lymphoma

Hodgkin’s Disease

Multiple Myeloma

Glioblastoma Multiforme

Malignant Glioma

Side Effects

The Most Common

More Common

Rare

Interaction

Pregnancy and Lactation

Pregnancy

Lactation

How should this medicine be used?

What special precautions should I follow?

Before receiving a carmustine injection,

Related medical topics

Related Articles

Prepare before seeing a doctor

Which doctor may help?

What to tell the doctor

Questions to ask

Tests to discuss

Avoid these mistakes

Medicine safety and first-aid guide

Safe first steps

OTC medicine safety

Avoid these mistakes

Get urgent help if

Patient health record and symptom diary

Care roadmap for: Carmustine – Uses, Dosage, Side Effects, Interaction

Check danger signs first

Record the symptom story

Visit a qualified clinician

Do only useful tests

Follow up and return early if worse

Explore related RX articles

To Get Daily Health Newsletter

Contraindication

Dosage

Brain/Intracranial Tumor